OTC · CIK 0000914139
PRKR PARKERVISION INC
Insider trading from SEC Form 4. Last filing Jan 26, 2026. Close $0.09 on Oct 9, 2026, +13% from the 52-week low and -77% from the high.
PARKERVISION INC (PRKR) has 15 SEC Form 4 filings on file from 5 insiders, the latest filed on Jan 26, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at PRKR. The newest: Lewis H Titterton jr (director) bought $1.0M of stock on Nov 18, 2025, filed Nov 18, 2025, scored 50 (moderate).
PRKR closed at $0.09 on Oct 9, 2026, 13% above its 52-week low and 77% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at PARKERVISION INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Lewis H Titterton jr director buy | $1.0M 4,761,905 shares | +125% | - |
Transactions
Every row filed, 24 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 22, 2026 | Jeffrey Parker Chief Executive Officer | AGrant or award Nonqualified Stock Option (Performance-Based)derivative | +8,000,000 | $0.24 | $1.9M | 8,000,000 | Jan 26, 2026 |
| Jan 22, 2026 | Robert Greene Sterne director | AGrant or award Option to Purchase Common Stockderivative | +370,000 | $0.24 | $89k | 370,000 | Jan 26, 2026 |
| Jan 22, 2026 | Lewis H Titterton jr director | AGrant or award Option to Purchase Common Stockderivative | +370,000 | $0.24 | $89k | 370,000 | Jan 26, 2026 |
| Jan 22, 2026 | Paul A Rosenbaum director | AGrant or award Option to Purchase Common Stockderivative | +370,000 | $0.24 | $89k | 370,000 | Jan 26, 2026 |
| Jan 22, 2026 | Cynthia L French Chief Financial Officer | AGrant or award Nonqualified Stock Optionderivative | +500,000 | $0.24 | $120k | 500,000 | Jan 26, 2026 |
| Jan 22, 2026 | Cynthia L French Chief Financial Officer | AGrant or award Nonqualified Stock Option (Performance-Based)derivative | +500,000 | $0.24 | $120k | 500,000 | Jan 26, 2026 |
| Nov 18, 2025 | Lewis H Titterton jr director | POpen-market purchase Common Stock | +4,761,905 | $0.21 | $1.0M | 8,578,170 | Nov 18, 2025 |
| Oct 7, 2025 | Lewis H Titterton jr director | MOption exercise Common Stock | +525,000 | $0.18 | $95k | 3,541,265 | Oct 7, 2025 |
| Oct 7, 2025 | Lewis H Titterton jr director | MOption exercise Common Stock | +275,000 | $0.20 | $55k | 3,816,265 | Oct 7, 2025 |
| Oct 7, 2025 | Lewis H Titterton jr director | MOption exercise Nonqualified Stock Optionderivative | -525,000 | $0.18 | $95k | 75,000 | Oct 7, 2025 |
| Oct 7, 2025 | Lewis H Titterton jr director | MOption exercise Nonqualified Stock Optionderivative | -275,000 | $0.20 | $55k | 0 | Oct 7, 2025 |
| Jul 3, 2025 | Lewis H Titterton jr director | AGrant or award Common stock | +275,000 | - | - | 3,153,765 | Jul 8, 2025 |
| Jul 3, 2025 | Paul A Rosenbaum director | AGrant or award Common Stock | +275,000 | - | - | 2,134,796 | Jul 8, 2025 |
| Jul 3, 2025 | Robert Greene Sterne director | AGrant or award Option to Purchase Common Stockderivative | +300,000 | $0.29 | $87k | 300,000 | Jul 8, 2025 |
| May 8, 2025 | Cynthia L French Chief Financial Officer | GGift Common Stock | -25,000 | $0.00 | $0 | 166,583 | May 9, 2025 |
| May 6, 2025 | Lewis H Titterton jr director | CConversion Common Stock | +1,699,844 | $0.13 | $221k | 2,878,765 | May 9, 2025 |
| May 6, 2025 | Lewis H Titterton jr director | CConversion Convertible Notederivative | -1,699,844 | $0.13 | $221k | 0 | May 9, 2025 |
| Apr 15, 2025 | Jeffrey Parker Chief Executive Officer | JOther Nonqualified Stock Optionderivative | +0 | - | - | 8,000,000 | Apr 17, 2025 |
| Apr 15, 2025 | Cynthia L French Chief Financial Officer | JOther Nonqualified Stock Optionderivative | +0 | - | - | 1,000,000 | Apr 17, 2025 |
| Dec 31, 2024 | Paul A Rosenbaum director | AGrant or award Common Stock | +11,765 | $0.17 | $2,000 | 607,405 | Oct 31, 2024 |
| Oct 29, 2024 | Paul A Rosenbaum director | CConversion Common Stock | +816,924 | $0.13 | $106k | 1,424,329 | Oct 31, 2024 |
| Oct 29, 2024 | Paul A Rosenbaum director | CConversion Common Stock | +435,467 | $0.25 | $109k | 1,859,796 | Oct 31, 2024 |
| Oct 29, 2024 | Paul A Rosenbaum director | CConversion Convertible Notederivative | -816,924 | $0.13 | $106k | 0 | Oct 31, 2024 |
| Oct 29, 2024 | Paul A Rosenbaum director | CConversion Convertible Notederivative | -435,467 | $0.25 | $109k | 0 | Oct 31, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Cynthia L FrenchChief Financial Officer
- Jeffrey ParkerChief Executive Officer
- Paul A Rosenbaumdirector
- Robert Greene Sternedirector
- Lewis H Titterton jrdirector
Questions about PRKR
Answered from the filings on this page, as of the latest one.
Are insiders buying PRKR?
No. In the last 90 days no insider at PARKERVISION INC bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade PRKR on the open market?
Lewis H Titterton jr (director) bought $1.0M of PRKR on Nov 18, 2025 and filed the Form 4 on Nov 18, 2025. InsiderTell scored 50 (moderate).
How many insiders file Form 4 at PARKERVISION INC?
5 people have filed a Form 4 at PARKERVISION INC, among them Cynthia L French (Chief Financial Officer), Jeffrey Parker (Chief Executive Officer), Paul A Rosenbaum (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.